|Mr. Ronald Kempers||CEO, Pres & CFO||282k||N/A||1968|
|Dr. Sylvain Fleury||Chief Scientific Officer||282k||N/A||1962|
|Mr. Anthony Jessop||Sr. VP||N/A||N/A||1941|
|Dr. Antonius Johannes Stegmann||Head of R&D and Chief Scientific Officer of Mymetics BV||N/A||N/A||N/A|
|Mr. Mario Amacker Ph.D.||Head of Quality & Manufacturing||N/A||N/A||N/A|
Mymetics Corporation, a vaccine company, focuses on research and developing vaccines for infectious diseases in Switzerland. The company's product pipeline includes vaccine candidates, such as HIV-1/AIDS, intra nasal influenza, malaria, and chikungunya.It has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative; the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; RSV Corporation for developing the RSV vaccine; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.
Mymetics Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.